Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth To Seek Prevenar Otitis Media Indication In Future Submission

Executive Summary

Wyeth-Lederle plans to seek an indication for its pneumococcal conjugate vaccine Prevenar for the prevention of otitis media in a future submission to FDA.

You may also be interested in...



Wyeth-Lederle To Submit Monthly Adverse Events Reports For Prevnar

Wyeth-Lederle Vaccines is required to submit monthly reports of adverse events for Prevnar in its first year following approval.

Wyeth-Lederle To Submit Monthly Adverse Events Reports For Prevnar

Wyeth-Lederle Vaccines is required to submit monthly reports of adverse events for Prevnar in its first year following approval.

Wyeth Prevenar Approval Expected By End of February

Wyeth-Ayerst is expecting approval of its pneumococcal conjugate vaccine Prevenar by the end of February.

Related Content

UsernamePublicRestriction

Register

PS035186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel